Vir, Gilead Team up on Solid Tumor Cancer Therapies in up to $1.9 Billion Deal

Vir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal

Oct 14 (Reuters) - Vir Biotechnology said on Wednesday it had signed a collaboration agreement worth up to $1.88 ​billion with Gilead Sciences to ‌discover and develop new cancer treatments for solid tumors. Shares of Vir rose more than 10% in premarke...

Vir Biotechnology Enters R&D Collaboration with Gilead for Three Novel PRO-XTEN Dual Masked T-Cell Engagers

Gilead and Vir Biotechnology Enter a $1.87 billion collaboration to discover three PRO-XTEN dual-masked T-cell engagers aimed at solid tumors.

Vir Biotechnology Shares Rise Nearly 10% in Premarket After Gilead Deal

Gilead will use Vir’s PRO-XTEN platform to discover and develop cancer drugs under an agreement valued at up to nearly $1.9 billion.

Vir makes solid tumor T cell engager deal with Gilead

Vir Biotechnology and its CEO Marianne De Backer have notched yet another deal, this time with Gilead. Gilead will pay Vir $65 million upfront, with another $45 million in near-term milestones. Gilead's also paying a ...